Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

for Conference Participants, Conference Participants

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Nephropathic cystinosis is an autosomal recessive metabolic, lifelong disease characterized by lysosomal cystine accumulation throughout the body that commonly presents in infancy with a renal Fanconi syndrome and, if untreated, leads to end-stage kidney disease (ESKD) in the later childhood years. The molecular basis is due to mutations in CTNS, the gene encoding for the lysosomal cystine-proton cotransporter, cystinosin. During adolescence and adulthood, extrarenal manifestations of cystinosis develop and require multidisciplinary care. Despite substantial improvement in prognosis due to cystine-depleting therapy with cysteamine, no cure of the disease is currently available. Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on cystinosis to review the state-of-the-art knowledge and to address areas of controversies in pathophysiology, diagnostics, monitoring, and treatment in different age groups. More importantly, promising areas of investigation that may lead to optimal outcomes for patients afflicted with this lifelong, systemic disease were discussed with a research agenda proposed for the future.

Original languageEnglish (US)
Pages (from-to)1192-1203
Number of pages12
JournalKidney international
Volume89
Issue number6
DOIs
StatePublished - Jan 1 2016

Keywords

  • biomarker
  • cell signaling
  • chronic kidney disease
  • cystinosin
  • end-stage kidney disease
  • rare kidney diseases

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference'. Together they form a unique fingerprint.

  • Cite this